[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE14423T1 - Hydroxamsaeurederivate vom typ der mannich-basen mit verbesserter biologischer verfuegbarkeit von nicht-steroiden entzuendungshemmern, verfahren zur herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzung. - Google Patents

Hydroxamsaeurederivate vom typ der mannich-basen mit verbesserter biologischer verfuegbarkeit von nicht-steroiden entzuendungshemmern, verfahren zur herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzung.

Info

Publication number
ATE14423T1
ATE14423T1 AT81103066T AT81103066T ATE14423T1 AT E14423 T1 ATE14423 T1 AT E14423T1 AT 81103066 T AT81103066 T AT 81103066T AT 81103066 T AT81103066 T AT 81103066T AT E14423 T1 ATE14423 T1 AT E14423T1
Authority
AT
Austria
Prior art keywords
compounds
inflammatory agents
preparation
pharmaceutical composition
composition containing
Prior art date
Application number
AT81103066T
Other languages
English (en)
Inventor
Kenneth B Sloan
Roy Little
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE14423T1 publication Critical patent/ATE14423T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT81103066T 1980-04-24 1981-04-23 Hydroxamsaeurederivate vom typ der mannich-basen mit verbesserter biologischer verfuegbarkeit von nicht-steroiden entzuendungshemmern, verfahren zur herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzung. ATE14423T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14352080A 1980-04-24 1980-04-24
EP81103066A EP0039051B1 (de) 1980-04-24 1981-04-23 Hydroxamsäurederivate vom Typ der Mannich-Basen mit verbesserter biologischer Verfügbarkeit von nicht-steroiden Entzündungshemmern, Verfahren zur Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzung

Publications (1)

Publication Number Publication Date
ATE14423T1 true ATE14423T1 (de) 1985-08-15

Family

ID=22504442

Family Applications (1)

Application Number Title Priority Date Filing Date
AT81103066T ATE14423T1 (de) 1980-04-24 1981-04-23 Hydroxamsaeurederivate vom typ der mannich-basen mit verbesserter biologischer verfuegbarkeit von nicht-steroiden entzuendungshemmern, verfahren zur herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzung.

Country Status (9)

Country Link
EP (1) EP0039051B1 (de)
JP (1) JPS56167643A (de)
AT (1) ATE14423T1 (de)
DE (1) DE3171467D1 (de)
DK (1) DK156717C (de)
ES (1) ES501573A0 (de)
GR (1) GR74496B (de)
IE (1) IE53001B1 (de)
PT (1) PT72878B (de)

Families Citing this family (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943587A (en) * 1988-05-19 1990-07-24 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition
US5112868A (en) * 1988-05-19 1992-05-12 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition
US5068251A (en) * 1988-12-16 1991-11-26 Abbott Laboratories Lipoxygenase inhibiting compounds
US5212189A (en) * 1991-12-17 1993-05-18 Warner-Lambert Company Thiadiazole or oxadiazole analogs of fenamic acids containing substituted hydroxamate side chains as antiinflammatory agents
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6335329B1 (en) 1997-12-19 2002-01-01 Amgen Inc. Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
US6107291A (en) * 1997-12-19 2000-08-22 Amgen Inc. Azepine or larger medium ring derivatives and methods of use
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
DE60335635D1 (de) 2002-05-22 2011-02-17 Amgen Inc Aminopyrimidin-derivate zur verwendung als vanilloid-rezeptor-liganden zur behandlung von schmerzen
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
KR20050055694A (ko) 2002-08-08 2005-06-13 암젠 인코포레이티드 바닐로이드 수용체 리간드 및 치료시 이들의 용도
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7582631B2 (en) 2004-01-14 2009-09-01 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7429616B2 (en) 2005-07-15 2008-09-30 Board Of Regents, University Of Texas System Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
RU2008142598A (ru) 2006-03-29 2010-05-10 Новартис АГ (CH) Селективные гидроксаматные ингибиторы ммп
CA2787343C (en) 2006-06-26 2016-08-02 Amgen Inc. Compositions comprising modified lcat and uses thereof
EP2049115B1 (de) 2006-07-14 2013-08-21 Amgen Inc. Alkyn-substituierte pyridonverbindungen und verfahren zu ihrer verwendung
CA2658462C (en) 2006-07-20 2011-09-27 Amgen Inc. Substituted pyridone compounds and methods of use
CA2658190C (en) 2006-07-20 2013-01-29 Amgen Inc. Di-amino-substituted heterocyclic compounds and methods of use
AU2007276433B2 (en) 2006-07-20 2011-06-16 Novartis Ag Amino-piperidine derivatives as CETP inhibitors
AU2008231304B2 (en) 2007-03-23 2011-05-12 Amgen Inc. Heterocyclic compounds and their uses
EA022912B1 (ru) 2007-11-05 2016-03-31 Новартис Аг Производные 4-бензиламино-1-карбоксиацилпиперидина как ингибиторы бпхэ (белка-переносчика холестерилового эфира), применимые для лечения заболеваний, таких как гиперлипидемия или артериосклероз
US8759365B2 (en) 2007-12-03 2014-06-24 Novartis Ag Organic compounds
EP2268612B1 (de) 2008-03-24 2014-08-20 Novartis AG Matrix-metalloproteinaseinhibitoren auf arylsulfonamidbasis
CA2746307C (en) 2008-12-17 2013-11-19 Amgen Inc. Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
WO2010085968A1 (en) 2008-12-30 2010-08-05 European Molecular Biology Laboratory (Embl) Toluidine sulfonamides and their use as hif-inhibitors
WO2010075869A1 (en) 2008-12-30 2010-07-08 European Molecular Biology Laboratory (Embl) Toluidine sulfonamides and their use
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
BRPI1010600A2 (pt) 2009-05-15 2016-03-15 Novartis Ag aril piridina como inibidores de aldosterona sintase
AU2010251967B9 (en) 2009-05-28 2014-04-03 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
KR20120041702A (ko) 2009-05-28 2012-05-02 노파르티스 아게 네프릴리신 억제제로서의 치환된 아미노부티르산 유도체
SG176986A1 (en) 2009-06-25 2012-02-28 Amgen Inc Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
AU2010265971B2 (en) 2009-06-25 2014-08-14 Amgen Inc. Heterocyclic compounds and their uses as inhibitors of PI3 K activity
WO2010151735A2 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
WO2010151791A1 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
UY32799A (es) 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
IN2012DN01693A (de) 2009-08-26 2015-06-05 Novartis Ag
SG178965A1 (en) 2009-09-03 2012-04-27 Allergan Inc Compounds as tyrosine kinase modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
KR20120049940A (ko) 2009-09-04 2012-05-17 노파르티스 아게 키나제 억제제로서의 헤테로아릴 화합물
MX2012002761A (es) 2009-09-04 2012-04-19 Novartis Ag Bipiridinas utiles para el tratamiento de enfermedades proliferativas.
KR20120076352A (ko) 2009-09-04 2012-07-09 노파르티스 아게 증식성 질환의 치료에 유용한 피라지닐피리딘
AR078770A1 (es) 2009-10-27 2011-11-30 Elara Pharmaceuticals Gmbh Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
EP2501678B1 (de) 2009-11-17 2015-09-23 Novartis AG Aryl-pyridin derivate als aldosteron synthase hemmer
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
EP2507234B1 (de) 2009-11-30 2014-03-12 Novartis AG Imidazolderivate als aldosteron-synthasehemmer
EP2513109A1 (de) 2009-12-18 2012-10-24 Amgen Inc. Heterocyclische verbindungen und ihre verwendung
WO2011073316A1 (en) 2009-12-18 2011-06-23 Novartis Ag 4-aryl-butane-1,3-diamides
TW201132642A (en) 2009-12-21 2011-10-01 Novartis Ag Diaza-spiro[5.5]undecanes
US8742106B2 (en) 2009-12-21 2014-06-03 Novartis Ag Disubstituted heteroaryl-fused pyridines
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
CA2800578A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen-heterocyclic compounds as phosphodiesterase 10 inhibitors
JP5702855B2 (ja) 2010-05-13 2015-04-15 アムジエン・インコーポレーテツド Ｐｄｅ１０阻害剤として有用な窒素複素環化合物
EP2569306A1 (de) 2010-05-13 2013-03-20 Amgen Inc. Heteroaryloxycarbocyclylverbindungen als pde10-hemmer
JP2013526546A (ja) 2010-05-13 2013-06-24 アムジエン・インコーポレーテツド Ｐｄｅ１０阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物
CN102947275A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 哌啶基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
JP2013528635A (ja) 2010-06-17 2013-07-11 ノバルティス アーゲー ビフェニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
WO2012003264A1 (en) 2010-06-30 2012-01-05 Amgen Inc. Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors
AU2011272857A1 (en) 2010-06-30 2013-01-10 Amgen Inc. Quinolines as P13K inhibitors
MX2012015147A (es) 2010-06-30 2013-05-01 Amgen Inc Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
US8759371B2 (en) 2010-07-01 2014-06-24 Amgen Inc. Heterocyclic compounds and their uses
AU2011272853A1 (en) 2010-07-01 2013-01-10 Amgen Inc. Heterocyclic compounds and their use as inhibitors of PI3K activity
EP2588469A1 (de) 2010-07-02 2013-05-08 Amgen Inc. Heterozyklische verbindungen und ihre verwendung als hemmer der pi3k-aktivität
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
AU2011278825B2 (en) 2010-07-13 2012-09-20 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
JP5781159B2 (ja) 2010-07-14 2015-09-16 ノバルティス アーゲー Ｉｐ受容体アゴニストヘテロ環式化合物
US9040690B2 (en) 2010-07-22 2015-05-26 Novartis Ag 2,3,5-trisubstituted thiophene compounds and uses thereof
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
RS54544B1 (en) 2010-09-13 2016-06-30 Novartis Ag TRIAZINE-OXADIAZOLES
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
ES2610360T3 (es) 2010-09-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Compuestos de imidazotriazinona
US20120101110A1 (en) 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
AU2011323243A1 (en) 2010-11-04 2013-05-23 Amgen Inc. Heterocyclic compounds and their uses
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
JP2013543000A (ja) 2010-11-17 2013-11-28 アムジエン・インコーポレーテツド 複素環化合物およびその使用
US9090593B2 (en) 2010-12-09 2015-07-28 Amgen Inc. Bicyclic compounds as Pim inhibitors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
US20140039007A1 (en) 2010-12-20 2014-02-06 David C. Tully Compositions and methods for modulating farnesoid x receptors
WO2012087520A1 (en) 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
MX2013007261A (es) 2010-12-23 2013-11-04 Amgen Inc Compuestos heterociclicos y sus usos.
MX347391B (es) 2011-01-04 2017-04-25 Novartis Ag Compuestos de indol o análogos de los mismos útiles para el tratamiento de degeneración macular relacionada con la edad (amd).
EA201391033A1 (ru) 2011-01-13 2014-01-30 Новартис Аг Ингибиторы bace-2 для лечения метаболических расстройств
WO2012101065A2 (en) 2011-01-28 2012-08-02 Novartis Ag Pyrimidine biaryl amine compounds and their uses
WO2012101063A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
AU2012230890A1 (en) 2011-03-22 2013-09-26 Amgen Inc. Azole compounds as Pim inhibitors
WO2012130306A1 (en) 2011-03-30 2012-10-04 Elara Pharmaceuticals Gmbh Bicyclic 2,3-dihyrdobenzazine compounds for use in therapy
WO2012130314A1 (en) 2011-03-31 2012-10-04 Elara Pharmaceuticals Gmbh Composition comprising docetaxel
EP2691392A1 (de) 2011-03-31 2014-02-05 EMBLEM Technology Transfer GmbH Imidazo [1,2-a] pyridinverbindungen zur verwendung in der therapie
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
US9187486B2 (en) 2011-04-29 2015-11-17 Amgen Inc. Bicyclic pyridazine compounds as Pim inhibitors
US8778941B2 (en) 2011-06-24 2014-07-15 Amgen Inc. TRPM8 antagonists and their use in treatments
CN103906733A (zh) 2011-06-24 2014-07-02 安姆根有限公司 Trpm8拮抗剂及其在治疗中的用途
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
US20140249139A1 (en) 2011-10-21 2014-09-04 Novartis Ag Quinazoline Derivatives
UY34572A (es) 2012-01-13 2013-09-02 Novartis Ag Compuestos heterocíclicos agonistas del receptor ip
WO2013105063A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US20140357641A1 (en) 2012-01-13 2014-12-04 Novartis Ag IP receptor agonist heterocyclic compounds
US9115129B2 (en) 2012-01-13 2015-08-25 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
US20140378463A1 (en) 2012-01-13 2014-12-25 Novartis Ag IP receptor agonist heterocyclic compounds
TW201348226A (zh) 2012-02-28 2013-12-01 Amgen Inc 作為ｐｉｍ抑制劑之醯胺
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
WO2013142269A1 (en) 2012-03-19 2013-09-26 Envivo Pharmaceuticals, Inc. Imidazotriazinone compounds
DK2834231T3 (en) 2012-04-04 2016-04-18 Amgen Inc HETEROCYCLIC COMPOUNDS AND THEIR USES
AP2014008040A0 (en) 2012-05-04 2014-10-31 Novartis Ag Complement pathway modulators and uses thereof
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
EP2861578A1 (de) 2012-06-06 2015-04-22 Irm Llc Verbindungen und zusammensetzungen zur modulation der egfr-aktivität
AR091436A1 (es) 2012-06-14 2015-02-04 Amgen Inc Compuestos de azetidina y piperidina utiles como inhibidores de pde10
AU2013277154A1 (en) 2012-06-20 2014-12-18 Jonathan E. Grob Complement pathway modulators and uses thereof
ES2712190T3 (es) 2012-06-28 2019-05-09 Novartis Ag Moduladores de la vía del complemento y sus usos
WO2014002053A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
JP6154897B2 (ja) 2012-06-28 2017-06-28 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
CA2876993A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
JP6155332B2 (ja) 2012-06-28 2017-06-28 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
JP6273274B2 (ja) 2012-06-28 2018-01-31 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
ES2687983T3 (es) 2012-07-12 2018-10-30 Novartis Ag Moduladores de la ruta del complemento y usos de los mismos
WO2014022752A1 (en) 2012-08-03 2014-02-06 Amgen Inc. Macrocycles as pim inhibitors
WO2014023329A1 (en) 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
EP2895462A1 (de) 2012-09-13 2015-07-22 Baden-Württemberg Stiftung gGmbH Spezifische inhibitoren von protein p21 als therapeutika
WO2014125413A1 (en) 2013-02-13 2014-08-21 Novartis Ag Ip receptor agonist heterocyclic compounds
CU24330B1 (es) 2013-02-14 2018-03-13 Novartis Ag Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
WO2015019286A1 (en) 2013-08-07 2015-02-12 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment friedreich's ataxia
EP2924026A1 (de) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexane als JAK-Hemmer
WO2016088082A1 (en) 2014-12-05 2016-06-09 Novartis Ag Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof
WO2016151066A1 (en) 2015-03-24 2016-09-29 Helmholtz-Zentrum für Infektionsforschung GmbH Inhibitors of pseudomonas aeruginosa lecb
ES2770128T3 (es) 2015-04-30 2020-06-30 Recordati Ag Derivados de pirazol tricíclicos condensados útiles para modular los receptores farnesoide x
CA2994859A1 (en) 2015-08-19 2017-02-23 Vivus, Inc. Pharmaceutical formulations
CN105418480B (zh) * 2015-11-16 2019-05-10 青岛大学 2-(1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1氢-吲哚-3-基)-n-羟基乙酰胺的制备和应用
MX2018007432A (es) 2015-12-18 2018-09-21 Amgen Inc Compuestos de dihidroquinolinsulfonamida de alquilo.
MX2018007511A (es) 2015-12-18 2018-09-18 Amgen Inc Compuestos de alquinil dihidroquinolina sulfonamida.
AU2018217963B2 (en) 2017-02-10 2020-11-19 Novartis Ag 1-(4-amino-5-bromo-6-(1 H-pyrazol-1-yl)pyrimidin-2-yl)-1 H-pyrazol-4-ol and use thereof in the treatment of cancer
US20210147405A1 (en) 2017-06-14 2021-05-20 European Molecular Biology Laboratory Bicyclic heteroaromatic urea or carbamate compounds for use in therapy
CN110997663A (zh) 2017-06-14 2020-04-10 欧洲分子生物学实验室 用于疗法的苯并呋喃脲或氨基甲酸酯及其杂芳族类似物
US20200216435A1 (en) 2017-06-14 2020-07-09 European Molecular Biology Laboratory Bicyclic heteroaromatic amide compounds for use in therapy
CN110997664A (zh) 2017-06-14 2020-04-10 欧洲分子生物学实验室 用于疗法的苯并呋喃酰胺及其杂芳族类似物
BR112020015985A2 (pt) 2018-02-06 2020-12-15 Universität Heidelberg Composto, composição farmacêutica e kit
WO2019154859A1 (en) 2018-02-06 2019-08-15 Universität Heidelberg Fap inhibitor
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
GB201811825D0 (en) 2018-07-19 2018-09-05 Benevolentai Bio Ltd Organic compounds
GB201813791D0 (en) 2018-08-23 2018-10-10 Benevolental Bio Ltd Organic compounds
EA202191730A1 (ru) 2018-12-20 2021-08-24 Эмджен Инк. Ингибиторы kif18a
AU2019403488A1 (en) 2018-12-20 2021-06-24 Amgen Inc. KIF18A inhibitors
US20220056015A1 (en) 2018-12-20 2022-02-24 Amgen Inc. Kif18a inhibitors
US20220002311A1 (en) 2018-12-20 2022-01-06 Amgen Inc. Kif18a inhibitors
MX2022001181A (es) 2019-08-02 2022-02-22 Amgen Inc Inhibidores de kif18a.
CN114302880A (zh) 2019-08-02 2022-04-08 美国安进公司 Kif18a抑制剂
US20220372018A1 (en) 2019-08-02 2022-11-24 Amgen Inc. Kif18a inhibitors
JP2022542319A (ja) 2019-08-02 2022-09-30 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤
CA3159906A1 (en) 2019-11-05 2021-05-14 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Bivalent leca inhibitors targeting biofilm formation of pseudomonas aeruginosa
CN115297863A (zh) 2020-01-22 2022-11-04 博善人工智能生物科技有限公司 包含咪唑并[1,2-b]哒嗪化合物的表面药物组合物
KR20220131267A (ko) 2020-01-22 2022-09-27 베네볼런트에이아이 바이오 리미티드 약제학적 조성물 및 이의 용도
IL297242A (en) 2020-04-14 2022-12-01 Amgen Inc kif18a inhibitors for the treatment of neoplastic diseases
WO2021234181A1 (en) 2020-05-22 2021-11-25 Universität Heidelberg Use of fap inhibitor in a method of diagnosis
JP2021195368A (ja) 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
JP2021195367A (ja) 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
US20240025849A1 (en) 2020-08-26 2024-01-25 Max Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Inhibitors of no production
TW202237095A (zh) 2020-12-03 2022-10-01 德商艾斯巴赫生物有限公司 Ａｌｃ１抑制劑及與ｐａｒｐｉ之協同性
CA3201844A1 (en) 2020-12-17 2022-06-23 William W. Bachovchin Fap-activated radiotheranostics, and uses related thereto
CN118891042A (zh) 2021-10-29 2024-11-01 艾斯巴赫生物有限公司 与新型变构结合位点结合的病毒解旋酶抑制剂
TW202348228A (zh) 2022-02-24 2023-12-16 德商艾斯巴赫生物有限公司 病毒組合療法
WO2023213833A1 (en) 2022-05-02 2023-11-09 Eisbach Bio Gmbh Use of alc1 inhibitors and synergy with parpi
WO2024022332A1 (en) 2022-07-26 2024-02-01 Shanghai Sinotau Biotech. Co., Ltd Fap inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1081993A (en) * 1963-04-17 1967-09-06 Ici Ltd Difluoramino compounds
US3336194A (en) * 1963-04-30 1967-08-15 Merck & Co Inc Indolyl acid amides
US3417096A (en) * 1965-07-01 1968-12-17 Bristol Myers Co Certain 5(1-benzoyl-3-indolylmethyl) tetrazoles
IT1036004B (it) * 1968-05-21 1979-10-30 Abc Ist Biolog Chem Spa Acidt 3 indolil adetoidrossamici
FI55181C (fi) * 1970-09-09 1979-06-11 Ciba Geigy Ag Foerfarande foer framstaellning av nya farmaceutiskt effektiva fenylacethydroxamsyror
US4206220A (en) * 1978-07-13 1980-06-03 Interx Research Corporation Prodrugs for the improved delivery of non-steroidal anti-inflammatory agents

Also Published As

Publication number Publication date
EP0039051A3 (en) 1982-05-26
JPH04982B2 (de) 1992-01-09
EP0039051B1 (de) 1985-07-24
ES8207508A1 (es) 1982-09-16
IE53001B1 (en) 1988-05-11
DK156717C (da) 1990-02-19
PT72878A (en) 1981-05-01
DK182081A (da) 1981-10-25
GR74496B (de) 1984-06-28
DK156717B (da) 1989-09-25
JPS56167643A (en) 1981-12-23
IE810899L (en) 1981-10-24
PT72878B (en) 1983-03-29
ES501573A0 (es) 1982-09-16
EP0039051A2 (de) 1981-11-04
DE3171467D1 (en) 1985-08-29

Similar Documents

Publication Publication Date Title
ATE14423T1 (de) Hydroxamsaeurederivate vom typ der mannich-basen mit verbesserter biologischer verfuegbarkeit von nicht-steroiden entzuendungshemmern, verfahren zur herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzung.
ATE25974T1 (de) Acyl-substituierte derivate von 1,2,3,4tetrahydroisochinolin-3-carboxysaeuren, ihre salze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung.
ATE79376T1 (de) Dithioacetal-verbindungen, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ES2197160T3 (es) Antagonistas fibronogeno bicicliclos.
ATE63124T1 (de) Prodrugverbindungen, verfahren zu deren herstellung und diese enthaltende zubereitungen mit verzoegerter freisetzung.
ATE27701T1 (de) 2-carbamimidoyl-6-substituierte-1-carbadethiape - 2-em-3-carbonsaeure, verfahren zur herstellung und sie enthaltendes antibiotisches arzneipraeparat.
CA2036905A1 (en) Condensed thiazole compounds, their production and use
MX9202975A (es) Nuevos compuestos biciclicos y sus sales farmaceuticamente aceptables y procedimiento para su preparacion.
ATE19773T1 (de) Nitroaliphatische verbindungen, verfahren zu deren herstellung und deren verwendung.
ATE141606T1 (de) Cephemverbindungen und verfahren zu ihrer herstellung
ES460286A1 (es) Un procedimiento de preparacion de espiro(1,3-dioxolan-4,3) quinuclidina.
US2844510A (en) Phosphoric acid derivatives of 1-phenyl-2, 3-dimethyl-4-amino-5-pyrazolone
ATE16278T1 (de) Hydroxybenzylamino-aryl verbindungen, verfahren zur deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen.
ATE18667T1 (de) Aethenylimidazol-derivate, verfahren zu deren herstellung und deren pharmazeutische zusammensetzungen, bei deren herstellung verwendbare zwischenprodukte und verfahren zu deren herstellung.
KR900018082A (ko) 페닐알카노산의 에스테르
ATE7137T1 (de) Nitrosoureum-derivate, verfahren zu deren herstellung, und diese enthaltende pharmazeutische zusammensetzungen.
SE395895B (sv) Sett att framstella acylerade 6-aminopenicillansyraforeningar
ES8105286A1 (es) Un procedimiento para la preparacion de nuevos derivados de dihidropiridina.
JPS5589257A (en) New easily-absorbable sulfur-containing prodrug of non- steroidal antiphlogistic, and their drug compositions
GB1434645A (en) Tetrazole coumarin derivatives
GB1042199A (en) Certain substituted ª‰-alkyl and ª‰-cycloalkylamino-propionamides

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee